Repligen Corp. 10-Q Summary: Quarter Ended September 30, 2003
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2003, and the six months ended on that date. Repligen Corporation is a biotechnology company developing novel therapeutics for neuropsychiatric disorders (autism, schizophrenia) and autoimmune disorders. The company funds its proprietary drug development through profits from specialty pharmaceutical products, specifically Protein A (for chromatography) and SecreFlo (synthetic secretin).
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 2003 | 6 Months Ended Sep 30, 2003 |
|---|---|---|
| Total Revenue | $1,418,955 | $3,479,916 |
| Gross Profit | $678,485 (48% margin) | $1,883,857 (54% margin) |
| Net Loss | $(2,140,146) | $(4,167,998) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.14) |
| Cash and Marketable Securities | $27,754,196 (Total as of Sep 30, 2003) | |
| Working Capital | $13,942,695 (Sep 30, 2003) | |
| Debt | None reported; no debt arrangements reflected on balance sheet. |
Material Changes vs. Prior Period
- Revenue: Revenue decreased 16% ($268,000) in the three-month period compared to the prior year, driven by manufacturing issues at a significant Protein A customer and a delay in SecreFlo delivery. However, for the six-month period, revenue increased 5% ($173,000) due to SecreFlo sales, which were absent in the prior year's comparable period.
- Expenses: Operating expenses increased 29% ($648,000) for the quarter and 43% ($1.87 million) for the six months. Research and Development (R&D) expenses rose 52% for the quarter and 34% for the six months, primarily due to increased clinical trial and material costs. Selling, General, and Administrative (SG&A) expenses increased 54% for the six months due to SecreFlo marketing and litigation-related professional services.
- Profitability: Gross profit margins declined from 61% to 48% (quarterly) and 60% to 54% (six-month) due to product mix changes and the launch costs of SecreFlo.
- Liquidity: Cash and marketable securities increased by $8.8 million from the prior fiscal year-end, bolstered by a $11.8 million net proceeds from a private placement of common stock in May 2003.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to incur higher operating costs as clinical trials expand. The company believes it has sufficient funding to meet working capital and capital expenditure requirements for the next 24 months.
- Operational Updates: A lot of SecreFlo is undergoing quality control testing; if specifications are met, shipments are expected to resume in December 2003.
- Legal Proceedings: Repligen is appealing a District Court ruling against it in a patent dispute with Bristol-Myers Squibb regarding CTLA4-Ig inventorship. The outcome could restrict commercialization of CTLA4-Ig. Separately, Repligen received a Notice of Allowance for a patent covering CTLA4-Ig for rheumatoid arthritis, independent of the lawsuit.
- Risks: Key risks include the success of clinical trials, regulatory approvals, dependence on third-party manufacturers, and the ability to raise additional capital if needed.
Investor Verification Checklist
- SecreFlo Supply Chain: Verify the status of the SecreFlo lot currently in quality control testing and the timeline for resumed shipments.
- Patent Litigation: Monitor the appeal process against Bristol-Myers Squibb regarding CTLA4-Ig patent rights, as a loss could impact future revenue streams.
- Cash Burn Rate: Assess the sustainability of the current cash position ($27.7 million) against the accelerating R&D spend and operating losses.
- Customer Concentration: Note that three customers accounted for approximately 63% of revenue in the quarter ended September 30, 2003, creating concentration risk.